Exhibit 99.2
Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting
OXFORD, UK and PHILADELPHIA, Pa., May 13, 2015 — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data at the 18th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The data in this presentation pertain to the phenotypic and functional evaluation of engineered T cells targeting NY-ESO-1 in the blood of patients following infusion in Phase 1/2 clinical studies in synovial sarcoma and multiple myeloma patients. This presentation follows the data on persistence and clinical responses in both studies as presented at the recent AACR conference in Philadelphia, PA in April. The ASGCT meeting will take place at the Hyatt Regency in New Orleans, Louisiana, May 13 — 16, 2015.
Friday, May 15, 2015
Oral Presentation
Session title: Cancer — Immunotherapy, Cancer Vaccines I
Abstract number: 551
Presenter: Luca Melchiori, Ph.D., Senior Scientist at Adaptimmune
Title: “Enhanced-affinity NY-ESO-1-specific T cells exhibit extended functionality without exhaustion in a pattern of effector and memory programming in multiple cancer indications”
Presentation Time: 3:30 pm to 3:45 pm
Location: Empire D
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the company aims to utilize the body’s own machinery — the T cell — to target and destroy cancer cells by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune’s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The company currently has over 100 employees. For more information: http://www.adaptimmune.com
Forward-Looking Statements
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks